Cargando…

Bioavailability, Efficacy, Safety, and Regulatory Status of Creatine and Related Compounds: A Critical Review

In 2011, we published a paper providing an overview about the bioavailability, efficacy, and regulatory status of creatine monohydrate (CrM), as well as other “novel forms” of creatine that were being marketed at the time. This paper concluded that no other purported form of creatine had been shown...

Descripción completa

Detalles Bibliográficos
Autores principales: Kreider, Richard B., Jäger, Ralf, Purpura, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8912867/
https://www.ncbi.nlm.nih.gov/pubmed/35268011
http://dx.doi.org/10.3390/nu14051035
_version_ 1784667269945622528
author Kreider, Richard B.
Jäger, Ralf
Purpura, Martin
author_facet Kreider, Richard B.
Jäger, Ralf
Purpura, Martin
author_sort Kreider, Richard B.
collection PubMed
description In 2011, we published a paper providing an overview about the bioavailability, efficacy, and regulatory status of creatine monohydrate (CrM), as well as other “novel forms” of creatine that were being marketed at the time. This paper concluded that no other purported form of creatine had been shown to be a more effective source of creatine than CrM, and that CrM was recognized by international regulatory authorities as safe for use in dietary supplements. Moreover, that most purported “forms” of creatine that were being marketed at the time were either less bioavailable, less effective, more expensive, and/or not sufficiently studied in terms of safety and/or efficacy. We also provided examples of several “forms” of creatine that were being marketed that were not bioavailable sources of creatine or less effective than CrM in comparative effectiveness trials. We had hoped that this paper would encourage supplement manufacturers to use CrM in dietary supplements given the overwhelming efficacy and safety profile. Alternatively, encourage them to conduct research to show their purported “form” of creatine was a bioavailable, effective, and safe source of creatine before making unsubstantiated claims of greater efficacy and/or safety than CrM. Unfortunately, unsupported misrepresentations about the effectiveness and safety of various “forms” of creatine have continued. The purpose of this critical review is to: (1) provide an overview of the physiochemical properties, bioavailability, and safety of CrM; (2) describe the data needed to substantiate claims that a “novel form” of creatine is a bioavailable, effective, and safe source of creatine; (3) examine whether other marketed sources of creatine are more effective sources of creatine than CrM; (4) provide an update about the regulatory status of CrM and other purported sources of creatine sold as dietary supplements; and (5) provide guidance regarding the type of research needed to validate that a purported “new form” of creatine is a bioavailable, effective and safe source of creatine for dietary supplements. Based on this analysis, we categorized forms of creatine that are being sold as dietary supplements as either having strong, some, or no evidence of bioavailability and safety. As will be seen, CrM continues to be the only source of creatine that has substantial evidence to support bioavailability, efficacy, and safety. Additionally, CrM is the source of creatine recommended explicitly by professional societies and organizations and approved for use in global markets as a dietary ingredient or food additive.
format Online
Article
Text
id pubmed-8912867
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89128672022-03-11 Bioavailability, Efficacy, Safety, and Regulatory Status of Creatine and Related Compounds: A Critical Review Kreider, Richard B. Jäger, Ralf Purpura, Martin Nutrients Article In 2011, we published a paper providing an overview about the bioavailability, efficacy, and regulatory status of creatine monohydrate (CrM), as well as other “novel forms” of creatine that were being marketed at the time. This paper concluded that no other purported form of creatine had been shown to be a more effective source of creatine than CrM, and that CrM was recognized by international regulatory authorities as safe for use in dietary supplements. Moreover, that most purported “forms” of creatine that were being marketed at the time were either less bioavailable, less effective, more expensive, and/or not sufficiently studied in terms of safety and/or efficacy. We also provided examples of several “forms” of creatine that were being marketed that were not bioavailable sources of creatine or less effective than CrM in comparative effectiveness trials. We had hoped that this paper would encourage supplement manufacturers to use CrM in dietary supplements given the overwhelming efficacy and safety profile. Alternatively, encourage them to conduct research to show their purported “form” of creatine was a bioavailable, effective, and safe source of creatine before making unsubstantiated claims of greater efficacy and/or safety than CrM. Unfortunately, unsupported misrepresentations about the effectiveness and safety of various “forms” of creatine have continued. The purpose of this critical review is to: (1) provide an overview of the physiochemical properties, bioavailability, and safety of CrM; (2) describe the data needed to substantiate claims that a “novel form” of creatine is a bioavailable, effective, and safe source of creatine; (3) examine whether other marketed sources of creatine are more effective sources of creatine than CrM; (4) provide an update about the regulatory status of CrM and other purported sources of creatine sold as dietary supplements; and (5) provide guidance regarding the type of research needed to validate that a purported “new form” of creatine is a bioavailable, effective and safe source of creatine for dietary supplements. Based on this analysis, we categorized forms of creatine that are being sold as dietary supplements as either having strong, some, or no evidence of bioavailability and safety. As will be seen, CrM continues to be the only source of creatine that has substantial evidence to support bioavailability, efficacy, and safety. Additionally, CrM is the source of creatine recommended explicitly by professional societies and organizations and approved for use in global markets as a dietary ingredient or food additive. MDPI 2022-02-28 /pmc/articles/PMC8912867/ /pubmed/35268011 http://dx.doi.org/10.3390/nu14051035 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kreider, Richard B.
Jäger, Ralf
Purpura, Martin
Bioavailability, Efficacy, Safety, and Regulatory Status of Creatine and Related Compounds: A Critical Review
title Bioavailability, Efficacy, Safety, and Regulatory Status of Creatine and Related Compounds: A Critical Review
title_full Bioavailability, Efficacy, Safety, and Regulatory Status of Creatine and Related Compounds: A Critical Review
title_fullStr Bioavailability, Efficacy, Safety, and Regulatory Status of Creatine and Related Compounds: A Critical Review
title_full_unstemmed Bioavailability, Efficacy, Safety, and Regulatory Status of Creatine and Related Compounds: A Critical Review
title_short Bioavailability, Efficacy, Safety, and Regulatory Status of Creatine and Related Compounds: A Critical Review
title_sort bioavailability, efficacy, safety, and regulatory status of creatine and related compounds: a critical review
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8912867/
https://www.ncbi.nlm.nih.gov/pubmed/35268011
http://dx.doi.org/10.3390/nu14051035
work_keys_str_mv AT kreiderrichardb bioavailabilityefficacysafetyandregulatorystatusofcreatineandrelatedcompoundsacriticalreview
AT jagerralf bioavailabilityefficacysafetyandregulatorystatusofcreatineandrelatedcompoundsacriticalreview
AT purpuramartin bioavailabilityefficacysafetyandregulatorystatusofcreatineandrelatedcompoundsacriticalreview